MARTINSRIED, Germany, Dec. 10, 2008 (GLOBE NEWSWIRE) -- MorphoSys AG (Frankfurt:MOR.F - News) (Prime Standard Segment, TecDAX) today appointed Dr. Arndt Schottelius (42), as its first Chief Development Officer, responsible for coordinating the Group’s expanding therapeutic antibody development activities including pre-clinical and clinical drug development. Dr. Schottelius joins MorphoSys from Genentech Inc., South San Francisco, where he served as the Director of Immunology, Tissue Growth & Repair Early Development and most recently as Medical Director, Immunology Development, directing late-stage clinical development studies for the anti-CD20 antibodies Rituximab and Ocrelizumab in rheumatoid arthritis. Prior to his position at Genentech, Dr. Schottelius held science and management positions in immunology research at Berlex Biosciences, CA, USA, and Schering AG, Berlin, Germany. The appointment of Dr. Schottelius will take effect on December 29, 2008.
